methyl-3(3-allyl-4-hydroxyphenyl)propionate | 83812-23-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl-3(3-allyl-4-hydroxyphenyl)propionate
• 英文别名: 3-(3-Allyl-4-hydroxy-phenyl)-propionic acid methyl ester；methyl 3-(4-hydroxy-3-prop-2-enylphenyl)propanoate
• CAS: 83812-23-1
• 化学式: C₁₃H₁₆O₃
• 分子量: 220.268
• InChiKey: RMWKRLRYDYWTFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl-3(3-allyl-4-hydroxyphenyl)propionate 在 bis-triphenylphosphine-palladium(II) chloride 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-[2-(2-allyl-4-(2-methoxycarbonylethyl)phenyl)ethynyl]quinuclidin-3-ol
  参考文献：
  名称：

  Novel optimised quinuclidine squalene synthase inhibitors

  摘要：

  Optimised quinuclidine squalene synthase (SQS) inhibitors are reported; 3-[2-(2-allyl-4-(2-ethoxy carbonylethyl)phenyl)ethynyl]quinuclidin-3-ol 1c, is a potent inhibitor of rat (KI = 6 nM) and human (KI = 43 nM) microsomal SQS; the oral ED(50) of 1c, for the inhibition of rat cholesterol biosynthesis was 1.3+/-0.45 mg/kg and for the R-enantiomer 1m, 0.8+/-0.2 mg/kg, with the corresponding R-carboxylic acid 6a, being 0.9+/-0.25 mg/kg. (C) 1997 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(97)00053-x
• 作为产物：
  描述：

  对羟基苯丙酸甲酯 在 potassium carbonate 作用下， 以 二苯醚 、 丁酮 为溶剂， 生成 methyl-3(3-allyl-4-hydroxyphenyl)propionate
  参考文献：
  名称：

  Novel optimised quinuclidine squalene synthase inhibitors

  摘要：

  Optimised quinuclidine squalene synthase (SQS) inhibitors are reported; 3-[2-(2-allyl-4-(2-ethoxy carbonylethyl)phenyl)ethynyl]quinuclidin-3-ol 1c, is a potent inhibitor of rat (KI = 6 nM) and human (KI = 43 nM) microsomal SQS; the oral ED(50) of 1c, for the inhibition of rat cholesterol biosynthesis was 1.3+/-0.45 mg/kg and for the R-enantiomer 1m, 0.8+/-0.2 mg/kg, with the corresponding R-carboxylic acid 6a, being 0.9+/-0.25 mg/kg. (C) 1997 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(97)00053-x

文献信息

• Visible-Light-Induced Intramolecular C(sp²)–H Amination and Aziridination of Azidoformates via a Triplet Nitrene Pathway
  作者：Yipin Zhang、Xunqing Dong、Yanan Wu、Guigen Li、Hongjian Lu

  DOI：10.1021/acs.orglett.8b01980

  日期：2018.8.17

  Catalytic intramolecular C–H amination and aziridination reactions of o-allylphenyl azidoformates have been achieved under visible-light irradiation, providing a mild, clean, and efficient method for the synthesis of useful benzoxazolones and [5.1.0] bicyclic aziridines. Mechanistic studies suggest that a triplet nitrene acts as the reactive intermediate. The chemoselectivity of the reaction, with alkyl

  邻烯丙基苯基叠氮基甲酸酯的催化分子内C–H氨基化和叠氮化反应已在可见光照射下完成，为合成有用的苯并恶唑酮和[5.1.0]双环氮丙啶提供了温和，清洁和有效的方法。机理研究表明，三重态氮烯起反应性中间体的作用。与烷基烯烃叠氮化≫缺电子烯烃叠氮化≈C（sp 2）–H胺化≫ C（sp 3）–H胺化反应的化学选择性，在理解可见光方面可能具有指导意义诱导的三重态氮转化反应。
• Heterocyclic derivatives
  申请人：Zeneca Limited

  公开号：US05919793A1

  公开（公告）日：1999-07-06

  Compounds of formula (I) wherein R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 14 CR.sup.2 is a double bond; X is selected from --Ch.sub.2 CH.sub.2 --, --C.dbd.CH--, --C.tbd.C--, --CH.sub.2 O--, --OCH.sub.2, CH.sub.2 NH--, --NHCH.sub.2 --, --CH.sub.2 CO--, --COCH.sub.2 --, --CH.sub.2 S(O).sub.n -- and --S(O).sub.n CH.sub.2 -- (wherein n is 0, 1 or 2); Ar is phenyl which bears one or more substituents independently selected from the groups (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkoxycarbonyl, (1-6C)alkoxycarbonyl(1-6C)alkyl, (1-6C)alkoxy(1-6C)alkyl, (1-6C)alkylamino, di-\x9b(1-6C)alkyl!amino, carbamoyl, (1-6C) alkylcarbamoyl, di-\x9b(1-6C)alkyl!carbamoyl, (1-6C)alkenyl and oxime derivatives thereof and O--(1-6C)alkyl ethers of said oximes (1-6C)alkylthio, (1-6C)alkylsulphinyl and (1-6C)alkylsulphonyl when substituted by one or more groups selected from (1-6C)alkoxycarbonyl, (1-6C)alkanoyl and oxime derivatives thereof and O-(1-6C)alkyl ethers of said oxime derivatives, (1-6C)alkanoylamimo, (1-6C)alkanoyloxy, (1-6C)alkanoyloxy(1-6)alkyl, carbamoyl, N-(1-6C)alkylcarbamoyl, N,N-di\x9b(1-6C)alkyl!carbamoyl, amino, (1-6C)alkylamino, di-\x9b(1-6C)alkyl!amino, (1-6C)alkoxy, (2-6C)alkenyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, halogeno(1-6C)alkyl (2-6C)alkenyl, (2-6C)alkynyl, phenyl, phenoxy, cyano, nitro, hydroxy and carboxy; and wherein Ar may bear further substituents; and their pharmaceutically acceptable salts inhibit squalene synthese and are hence useful in lowering cholesterol levels in blood plasma Processes for preparing compounds of formula (I) are also referred to as well as pharmaceutical compositions containing them and their use in medicine.

  式(I)中的化合物，其中R.sup.1是氢或羟基；R.sup.2是氢；或R.sup.1和R.sup.2结合在一起，使得CR.sup.1 14 CR.sup.2是一个双键；X从--Ch.sub.2 CH.sub.2 --，--C.dbd.CH--，--C.tbd.C--，--CH.sub.2 O--，--OCH.sub.2，CH.sub.2 NH--，--NHCH.sub.2 --，--CH.sub.2 CO--，--COCH.sub.2 --，--CH.sub.2 S(O).sub.n --和--S(O).sub.n CH.sub.2 --中选择（其中n为0、1或2）；Ar是苯基，其上独立选择自基团（1-6C）烷基，（2-6C）烯基，（2-6C）炔基，（1-6C）烷氧基，（1-6C）烷氧羰基，（1-6C）烷氧羰基（1-6C）烷基，（1-6C）烷氧基（1-6C）烷基，（1-6C）烷基氨基，二-\x9b（1-6C）烷基！氨基，氨基甲酰基，（1-6C）烷基甲酰基，二-\x9b（1-6C）烷基！甲酰基，（1-6C）烯基和其氧肟衍生物和所述氧肟的O-（1-6C）烷基醚（1-6C）烷硫基，（1-6C）烷磺基和（1-6C）烷磺基，当被一个或多个基团选择时，从（1-6C）烷氧羰基，（1-6C）烷酰基和其氧肟衍生物和所述氧肟衍生物的O-（1-6C）烷基醚，（1-6C）烷酰胺基，（1-6C）烷酰氧基，（1-6C）烷酰氧基（1-6）烷基，氨基甲酰基，N-（1-6C）烷基甲酰基，N，N-二\x9b（1-6C）烷基！甲酰基，氨基，（1-6C）烷基氨基，二-\x9b（1-6C）烷基！氨基，（1-6C）烷氧基，（2-6C）烯氧基，（1-6C）烷硫基，（1-6C）烷磺基，（1-6C）烷磺基，卤代（1-6C）烷基（2-6C）烯基，（2-6C）炔基，苯基，苯氧基，氰基，硝基，羟基和羧基；其中Ar可能带有进一步的取代基；它们的药学上可接受的盐抑制角鲨烯合成，因此在降低血浆胆固醇水平方面有用。制备式(I)化合物的方法也被提及，以及含有它们的药物组合物及其在医学中的用途。
• Modulators of peroxisome proliferator activated receptors (ppar)
  申请人：Gossett Stacy Lynn

  公开号：US20050075378A1

  公开（公告）日：2005-04-07

  The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.

  本发明涉及一种I式化合物，以及其药学上可接受的盐、溶剂、水合物或立体异构体，该化合物在治疗X综合征、2型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉硬化以及与X综合征相关的其他疾病以及心血管疾病方面有用。
• MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR)
  申请人：Gossett Lynn Stacy

  公开号：US20080167310A1

  公开（公告）日：2008-07-10

  The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.

  本发明涉及公式I的化合物及其药学上可接受的盐、溶剂化合物、水合物或立体异构体，其可用于治疗X综合症、II型糖尿病、高血糖、高血脂、肥胖症、凝血异常、高血压、动脉硬化以及与X综合症和心血管疾病有关的其他疾病。
• Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them
  申请人：FISONS plc

  公开号：EP0056172A2

  公开（公告）日：1982-07-21

  There are described compounds of formula I, in which R is a group of formula II, R', R2 and R3, which may be the same or different each represent hydrogen, alkyl, alkenyl, alkenyloxy, halogen, alkoxy, alkanoyl or hydroxy, one or more of R4, R5 and R6 represents alkyl, alkanoyl, alkenyl, -COOH or -ACOOH where A represents Y, OY or SY and Y represents a -CH=CH-, methylene, ethylene or 1,3-propylene chain, and the remainder of R4, R5 and R' represent hydrogen, X represents a hydrocarbon chain having from 2 to 7 carbon atoms optionally substituted by hydroxy, E represents -S-, -0-, or -CH2-, and G represents -S- or -0-, (with various exceptions) and pharmaceutically acceptable derivatives of those compounds containing an acidic function. Processes for making the compounds of formula I, and the formulation and use of the compounds of formula I as antagonists of the slow reacting substance of anaphylaxis are also described.

  所述化合物为式 I、 其中 R 是式 II 的基团、 R'、R2 和 R3（可以相同或不同）各自代表氢、烷基、烯基、烯氧基、卤素、烷氧基、烷酰基或羟基，R4、R5 和 R6 中的一个或多个代表烷基、烷酰基、烯基、-COOH 或 -ACOOH 其中 A 代表 Y、OY 或 SY，Y 代表 -CH=CH-、亚甲基、亚乙基或 1，3-丙烯链、R4、R5 和 R' 的其余部分代表氢，X 代表具有 2 至 7 个碳原子可选被羟基取代的烃链，E 代表 -S-、-0- 或 -CH2-，G 代表 -S- 或 -0-，（有各种例外）以及这些化合物含有酸性官能团的药学上可接受的衍生物。 还描述了制造式 I 化合物的工艺，以及式 I 化合物作为过敏性休克慢反应物质拮抗剂的配方和用途。